Magnesium trisilicate compound tablets
Available from pharmacies, supermarkets, and retail outlets
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Aluminium hydroxide + Magnesium trisilicate
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
10 branded products available
MHRA licensed products
View all licensed products for Aluminium hydroxide + Magnesium trisilicate on the MHRA register
Magnesium trisilicate compound tablets
Magnesium trisilicate compound tablets
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 2 · 1988–2025
Showing the 50 most relevant studies, sorted by most relevant.
Daniel Krewski, Robert A. Yokel, Evert Nieboer, et al.
Journal of Toxicology and Environmental Health Part B, 2007
- Aluminum
- Aluminum Hydroxide
- Aluminum Oxide
S. Saha, Sayantan Ray, R. Acharya, et al.
Applied Clay Science, 2017
L. Haurie, A. I. Fernández, J. Velasco, et al.
Polymer Degradation and Stability, 2007
N. LeBozec, D. Thierry, D. Persson, et al.
Surface and Coatings Technology, 2019
Fernando Guerrero‐Romero, Oliver Micke, Luis E. Simental‐Mendía, et al.
Biology, 2023
Karin Elgar
Zenodo (CERN European Organization for Nuclear Research), 2021
Guowei Li, Jiawei Huang, Jian Zhou, et al.
Journal of Materials Chemistry A, 2024
J. Gembus, Vera Bracht, Florens Grimm, et al.
Journal of Physics D: Applied Physics, 2025
Plasma electrolytic oxidation (PEO) is a technique used to create oxide-ceramic coatings on lightweight metals, such as aluminium, magnesium, and titanium. PEO is known for producing coatings with high corrosion resistance and strong adhesion to the substrate. The process involves generating short-lived microdischarges on the material surface through anodic dielectric breakdown in a conductive aqueous solution. To investigate single microdischarges (SMDs) during PEO, a SMD setup was developed, where the active anode surface is reduced to the tip of a wire with a diameter of 1 mm. In this work the focus is on the effect of electrolyte concentration, anode material, and electrical parameters on the microdischarges. The electrolyte is composed of distilled water with varying concentrations of potassium hydroxide (0.5–4 g l−1). High-speed optical measurements are conducted to gain insights into the formation and temporal evolution of individual microdischarges and the induced gas bubble formation. Optical emission spectroscopy is used to estimate surface and electron temperatures by fitting Bremsstrahlung and Planck’s law to the continuum spectrum of the microdischarges. To evaluate the impact of the microdischarges on coating morphology, the resulting oxide layers on the metal tips are analysed using scanning electron microscopy. The study demonstrates that microdischarge behaviour is significantly influenced by the substrate material, treatment time, and electrolyte concentration, all of which impact the coating morphology. Under the conditions studied in this work, aluminium exhibits longer microdischarge and bubble lifetimes, with fewer cracks on the top layer of the coating, whereas titanium showed faster, shorter-lived bubbles due to more rapid microdischarge events.
Abstract licence: CC BY
Xiaojun Ren, Tongxi Lin, Bing Sun, et al.
Advanced Science, 2025
Graphene‐based materials have great potential for electrochemical energy storage applications, but their performance is often limited by the restacking of nanosheets, which restricts ion accessibility. In this study, a straightforward method to fabricate reduced graphene oxide (rGO) laminates intercalated with magnesium–aluminium layered double hydroxide (MgAl‐LDH) nanosheets is presented. Due to electrostatic interactions, the positively charged LDH nanosheets strongly bind to the negatively charged rGO layers, forming a stable, alternating laminar structure with well‐defined nano‐capillaries. Detailed characterization confirms the intended architecture of the rGO‐LDH hybrid. Electrochemical analysis shows nearly ideal electric double‐layer capacitor (EDLC) behavior, with the rGO‐LDH reaching a specific capacitance of up to 410 F g−1 at 1 A g−1. This work highlights the vital role of LDH nanosheets as interlayer spacers that effectively prevent restacking, providing new insights into designing 2D materials for high‐performance supercapacitors and energy storage systems.
Abstract licence: CC BY
Dan Persson, Alexander Wärnheim, N. LeBozec, et al.
Corrosion and Materials Degradation, 2025
The initial formation of corrosion products in pure humid air on magnesium alloys AZ91 and AZ31 was studied using infrared reflection absorption spectroscopy (IRRAS), infrared spectroscopic imaging, and SEM-EDS. The kinetics of corrosion product formation were monitored in situ with IRRAS during exposure to humid air (95% relative humidity) under two different CO2 concentrations: low (≤1 ppm) and ambient (400 ppm). For low CO2 concentrations, the primary corrosion product detected on both alloys was magnesium hydroxide (Mg(OH)2). In contrast, under ambient CO2 conditions (400 ppm), magnesium hydroxy carbonate was the dominant product. After 16 h of exposure, the amount of magnesium converted into corrosion products was approximately 8–10 times higher under low-CO2 conditions compared to ambient levels. The smaller formation of corrosion products but increased magnesium carbonate formation on AZ91D is attributed to its higher aluminium content compared to AZ31. Corrosion attack and product formation were largely localised to the centre of the α-phase in AZ91D, with the β-phase likely serving as sites for cathodic reactions.
Abstract licence: CC BY
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.